Field Force Sales Effectiveness

The integration challenge between CRM and claims data creates a 12-48 hour lag that makes field teams operate on outdated information. Most organizations export both datasets to Excel, manually match HCP identifiers, and then re-upload, losing a full day each week. Modern agentic analytics platforms like Tellius connect directly to both Salesforce and IQVIA through their semantic layer, automatically reconciling HCP identities and enabling real-time cross-source queries without manual intervention. It also ingests unstructured data from Gong call recordings and Google Drive documents to provide complete context about customer interactions beyond just structured CRM fields.

The delay between field activity and dashboard visibility stems from batch processing architectures where CRM data flows through multiple staging databases before reaching analytics tools. This creates a disconnect where field managers conduct Monday morning reviews using Thursday's data. Real-time analytics require either streaming data pipelines or platforms that query source systems directly rather than relying on overnight ETL (integrating data from multiple sources into a central repository) processes.

This is one of the most common complaints. A rep logs 15 calls in Salesforce, but the manager's dashboard shows 12, the IC system shows 14, and the territory ranking report shows 13. The problem is that each system applies different filters, date ranges, or call-type definitions without telling you. Salesforce might count all logged activities, your BI tool might filter out "administrative" calls, and IC systems might only count calls to targeted HCPs.

‍

Some systems use the call date, others use the sync date, and others use the "last modified" timestamp. Without a single source of truth built on unified data definitions and a shared semantic layer, you'll keep getting different answers depending on which screen you're looking at.

Physicians engage through multiple channels (attending webinars, opening emails, scheduling rep visits) but each interaction gets trapped in channel-specific silos. Creating a unified engagement score requires integrating email platforms, webinar systems, and CRM data into a single physician profile. Platforms with pre-built pharmaceutical connectors and identity resolution can stitch together the complete engagement journey without custom integration work.

‍

Most traditional Business Intelligence (BI) tools charge $50–$75 per user per month, so rolling them out to 5,000 reps becomes extremely expensive. At that scale, usage-based or compute-based pricing is much more efficient, especially when most reps only need read-only dashboard access instead of full authoring rights. A platform like Tellius that prices on data volume instead of named users lets you deploy analytics to the entire field force without costs increasing linearly with every additional rep.

‍

Most pharma companies still rely on weekly or monthly data feeds, which means reps are making calls based on prescribing patterns from 3-6 weeks ago. By the time you see that an HCP stopped writing or switched to a competitor, you've already wasted multiple visits. The lag comes from batch processing where data gets extracted, cleaned, matched to territories, and then loaded into reporting systems through overnight ETL jobs. Real-time or near-real-time analytics require streaming data pipelines or platforms that can query source systems directly and refresh dashboards within hours instead of days. Field teams operating on current-week data can respond to prescribing changes while they're happening, not after the damage is done.

‍

CRM dashboards excel at operational tracking but fail at cross-source intelligence that drives decisions. They show call counts but can't answer "which calls drove NBRx changes?" without claims data integration. CRM reports treat all HCPs equally, lacking the pharmaceutical context to weight by prescribing potential or formulary status. A specialized pharma analytics layer adds semantic understanding of NBRx/TRx relationships, payer dynamics, and territory potential that generic CRM reporting misses. This explains why even CRM users export to Excel for real analysis.

‍

Natural language analytics specifically designed for pharma can eliminate the analyst bottleneck that delays field decisions. Generic natural language tools often struggle with pharma because they don’t understand drug names or terms like “TRx,” “NBRx,” and “prior auth.” A pharma-specific platform needs a semantic layer and language models that are trained on industry terms and common question patterns. Tellius conversational AI Kaiya allows reps to ask "Which HCPs in my territory showed NBRx growth this month?" and receive instant answers because the semantic layer understands pharmaceutical terminology and relationships. Kaiya knows these terms and their connections to business outcomes. Field managers report getting answers in seconds that previously required 2-day analyst tickets, fundamentally changing how quickly teams can act on data insights.

Territory performance can look bad on paper even when a rep is doing a great job.

For example, one rep might work in an open-access market where most doctors are easy to see, while another rep is stuck in Integrated Delivery Networks (IDNs) where 70% of HCPs are “no-see.” If you just compare raw numbers (like calls, scripts, or sales), the second rep will always look worse—even if they’re actually doing more with less.

‍

So instead of judging reps only on standard metrics, analytics tools need to calculate “effective opportunity” for each territory. That means adjusting performance based on:

‍

• HCP accessibility (how many doctors can they realistically see?)
• Payer mix (are their patients mostly in plans with tougher coverage?)
• Formulary coverage (is the brand preferred, non-preferred, or not covred?)
• Competitive presence (how many strong competitors are already there?)

‍

When you factor in these things, you can see which territories are truly underperforming and which are just facing tougher market conditions.

To prove impact, you first need a clear baseline: how territories and individual HCPs were prescribing before reps increased activity or changed their approach. Then you compare how prescribing behaves afterward, looking at changes in NBRx and TRx for HCPs who were visited versus similar HCPs who were not, or territories with higher versus lower field intensity. At the HCP level, you track prescribing in the weeks after a visit and compare it to their own prior pattern and to a control group that didn’t receive a visit in that window.

‍

Throughout, you adjust for other factors that may have shifted at the same time, like formulary changes or competitor launches, so reps aren’t blamed or credited for things outside their control. Analytics platforms can automate these before/after and “treated vs. control” comparisons, so you don’t have to rebuild the logic every time you want to understand field contribution.

Annual territory realignment involves analyzing prescription data, account potential, rep capacity, and geographic constraints—typically through massive Excel models that break with large datasets. The process requires multiple iterations as stakeholders challenge assumptions and request scenarios. Automated territory optimization using AI agentic workflows can reduce alignment time to weeks by rapidly testing thousands of scenarios against balance, disruption, and potential metrics.

Territory realignments, HCP retirements, hospital system changes, and data vendor updates can all cause high-value targets to vanish from your call list without warning. Sometimes it's legitimate—an HCP retired or moved out of your territory. But often it's a data quality issue where IQVIA's provider match failed, a CRM sync error dropped records, or a territory optimization tool reassigned accounts based on outdated geocoding. The worst part is finding out weeks later when you notice NBRx dropped and realize you haven't been calling on a key writer. Analytics platforms need real-time alerts when high-value HCPs disappear from targeting lists and clear audit trails showing why accounts moved, so reps aren't blindsided by silent changes in their book of business.

Measuring MSL impact is tricky because they educate on science and safety, not sell, so classic sales metrics don’t really fit. Instead, you look at how prescribing patterns change 30–90 days after an MSL interaction, while controlling for other marketing efforts happening at the same time. Analytics tools that can run time-lagged correlation analysis within compliance rules help show how much MSL activity actually contributes to appropriate prescribing.

Yes. What-if modeling lets you test strategy changes before you spend the money. For example: “What happens if we increase call frequency by 20% on high-decile Healthcare Professionals (HCPs)?” or “What if we add a rep in the Southwest?”

‍

Simulation engines use historical response curves (how prescriptions responded in the past to changes in calls or coverage) to estimate future impact. These models get better over time as real results come in and recalibrate the predictions. Instead of arguing opinions in planning meetings, teams can rely on data-driven projections and expected ROI for different field force strategies.

Most dashboards are cluttered with activity metrics like calls, emails, and samples, but those don’t tell you if anything changed in prescribing.

• For HCP engagement, useful measures include NBRx per targeted HCP (how many new patients they actually start), share of voice versus competitors for that HCP, and some measure of “depth of engagement” that goes beyond just counting visits or emails.
• For territory performance, you want to compare actual results to the territory’s true potential, adjusted for payer access and restrictions.

Good analytics track how prescriptions change in the weeks after engagement and tie that back to HCP potential and access, so you can see whether reps are moving the needle where they reasonably can, instead of punishing them for barriers they don’t control. The organizations that get this right pick 5-7 clear “North Star” metrics that directly link field activity to business results, and then allow drill-down for deeper analysis when needed.

20% of physicians drive most New-to-Brand prescriptions (NBRx). High-potential HCPs are not just the ones writing the most prescriptions today. They are the ones who have the right patient mix, reasonable access, and room to grow. To find them, teams combine several views: current prescribing volume, how many eligible patients they see, payer mix and formulary status, and whether they are early adopters in the class. Many companies still try to do this in spreadsheets, pulling data from claims, CRM, and payer systems and hoping nothing breaks. A platform like Tellius can unify these sources and allow users to rank HCPs using multiple factors instead of just one metric.

Coverage gaps show up when important HCPs have few or no recent calls recorded, even though they treat many target patients or write in the category.

• Frequency issues often appear as irregular calling patterns, such as large bursts of activity at the end of the quarter and long gaps in between.
• Effectiveness problems show up when call volume is high, but prescriptions or new starts do not move in that account or territory.

By comparing call patterns, digital activity, and prescription trends together, teams can tell if the problem is “we are not there”, “we are not there often enough”, or “we are there, but the messages are not working”.

When a payer changes coverage, you can treat that as a before-and-after event and watch what happens to prescriptions linked to that payer.

• First, you identify HCPs with a high share of patients under the affected plan.
• Then you track their new starts and fills over the weeks and months after the change.
• You also compare them to HCPs or regions that were not affected, so you can separate a real access effect from general market noise.

‍

If you see prescriptions dropping mainly in the affected payer segment while other payers stay stable, that strongly suggests the formulary change is the main driver.

When performance changes, you usually need to test three main explanations: competition, access, and execution.

• Competitive impacts show up as shifts in market share while overall category volume stays similar.
• Access issues show up as more denials, more prior authorizations, or weaker pull-through in specific payer segments or regions.
• Engagement issues appear when prescribing drops but there is no major access or competitive change, and you can see fewer calls, territory vacancies, or weaker follow-through.

‍

Tellius can help by executing root cause analysis so you can see which of these patterns best explains the change.

Decile-based targeting is still useful. In pharma, deciles mean you rank all HCPs by how many prescriptions they write for your brand or category, then split them into 10 equal groups. The top deciles (for example, the top 20% of HCPs) usually drive most of the prescription volume (TRx/NBRx).

‍

The problem is that deciles are backward-looking. They tell you who wrote the most last year, not who is most likely to grow this year. AI models can spot “rising star” physicians who are not yet in the top deciles but have high potential based on patient mix changes, referral patterns, and competitive dynamics.

‍

The best approach is to combine both:

• Use deciles to prioritize proven high-volume HCPs for consistent coverage.
• Use AI to refresh target lists with emerging opportunities that traditional deciles miss.

‍

In short: deciles show “who wrote most last year”; AI shows “who could write more this year.”

Sales managers struggle because dashboards treat a 5-minute sample drop identically to a 60-minute clinical discussion. Leading organizations are shifting toward "high-impact insights" scoring that weights meaningful discussions about access barriers, treatment challenges, or competitive intelligence higher than routine check-ins.

‍

Tellius's AI agents can analyze call notes from CRM, actual conversation transcripts from Gong recordings, and follow-up documents stored in Google Drive to automatically score interaction quality based on real conversation content rather than just logged activities, identifying which engagement patterns drive actual prescription behavior.

Healthcare systems increasingly implement no-see policies or virtual-only restrictions, often catching field teams off-guard and destroying carefully planned call cycles. By analyzing patterns in appointment cancellations, decreasing interaction frequency, and hospital system communications, AI models can flag HCPs showing early signals of access restrictions. This allows teams to prioritize face-to-face engagement before doors close permanently.

Reps spend 30% of their time preparing for calls, manually researching each physician's prescribing history, patient population, and competitive usage. AI-powered pre-call planning can automatically generate briefings that include recent prescription trends, formulary changes affecting that HCP's patients, and suggested talking points based on similar successful interactions.

‍

Tellius's generative AI capabilities can create personalized, compliant pre-call briefs by synthesizing structured prescription data with unstructured sources like previous Gong call transcripts, email exchanges, and marketing collateral stored in Google Drive, ensuring reps have complete context including what was actually discussed in previous visits, not just what was logged in CRM.

Next-best-action engines analyze multiple signals to recommend where reps should spend time for maximum impact. AI models examine recent NBRx trends, HCP engagement history, formulary changes, competitive activity, and even unstructured call notes to predict which doctors are most likely to write new prescriptions if visited this week.

Rep and MSL insights often sit in free-text call notes, emails, or slide decks and never make it into actual decisions. The first step is to structure or tag those comments around common themes like “prior auth issue”, “competitor discount”, or “clinical objection” so they can be analyzed. Once tagged, you can line them up against claims trends, access metrics, and territory performance to see where the field story matches what is really happening in the data.

‍

From there, you track follow-up actions (for example, more hub support, payer pull-through, or new resources) and look at how prescribing or access changed afterward. Platforms like Tellius can analyze structured data side-by-side with coded call notes or Gong summaries, so you can see which field insights actually moved NBRx and should shape future strategy.

Early signs of HCP disengagement usually show up in behavior before you see a drop in prescriptions. Examples include cancelled or rescheduled meetings, shorter visit durations, fewer sample requests, and slower or lower response to emails or digital invitations. If an HCP who used to attend many programs or open most emails suddenly stops engaging, that is also a warning sign. By creating simple engagement scores based on these signals and tracking them over time, you can see which HCPs are drifting away.

Digital systems often know which HCPs opened emails, registered for webinars, or downloaded resources. Claims data shows who is actually prescribing the brand. When you connect these two views, you can find HCPs who show strong digital interest but have written few or no prescriptions. These HCPs are often good targets for focused outreach, because they already know the brand or topic but may be stuck on a specific concern, such as access, side effects, or how to start the first few patients.

‍